Antibodies to tumor endothelial marker 7R
Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors.
1. An isolated antibody that specifically binds to an epitope on the extracellular domain of TEM7R, comprising a heavy chain variable region comprising the complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO: 9, and a light chain variable region comprising the CDR1, CDR2, and CDR3 of SEQ ID NO: 10.
2. The antibody of claim 1 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9.
3. The antibody of claim 1 , wherein the light chain comprises the amino acid sequence of SEQ ID NO: 10.
4. The antibody of claim 1 , wherein the antibody is a monoclonal antibody comprising an Fc domain.
5. The antibody of claim 1 , wherein the antibody comprises a single chain Fv.
6. The antibody of claim 5 , wherein the single chain Fv comprises the amino acid sequence of SEQ ID NO: 11.
7. The antibody of claim 1 , wherein the affinity of the antibody for the epitope is less than about 1×10 −6 M.
8. The antibody of claim 1 , wherein the affinity of the antibody for the epitope is less than about 1×10 −8 M.
9. The antibody of claim 1 , wherein the affinity of the antibody for the epitope is less than about 1×10 −10 M.
10. The antibody of claim 1 , wherein the antibody is a chimeric antibody.
11. The antibody of claim 1 , wherein the antibody is a fully human antibody.
12. The antibody of claim 1 , wherein the antibody is conjugated to a chemotherapeutic agent.
13. The antibody of claim 1 , wherein the antibody is conjugated to a detectable label.
14. The antibody of claim 1 , wherein the TEM7R is human TEM7R.
15. The antibody of claim 1 , wherein the TEM7R is mouse TEM7R.
16. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
17. A kit comprising the antibody of claim 1 , and optionally a pharmaceutically acceptable carrier, and instructions for using the antibody in a method for inhibiting angiogenesis of a tumor.
18. The kit of claim 17 , wherein the antibody is conjugated to a chemotherapeutic agent.